BioCentury | Jun 3, 2010
Distillery Therapeutics

Indication: Endocrine disease

...Endocrine disease Diabetes Peptidylprolyl isomerase F (PPIF; cyclophilin D); pancreatic and duodenal homeobox 1 (PDX1; IPF1) Mouse...
BioCentury | May 28, 2009
Targets & Mechanisms

New angiogenesis targets

...Converts phosphatidic acid to diacylglycerol, a precursor to prostaglandins and leukotrienes Nimesulide and budesonide PPIH Peptidylprolyl isomerase...
BioCentury | May 21, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

...Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease Cyclophilin A (CYPA; peptidylprolyl isomerase...
BioCentury | Oct 2, 2008
Distillery Therapeutics

This Week in Therapeutics

...pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Cyclophilin D (CYPD; peptidylprolyl isomerase...
Items per page:
1 - 4 of 4